North America’s medical devices industry saw a drop of 11.40% in deal activity during September 2022, when compared with the last 12-month average, led by CVS Health’s $8bn acquisition of Signify Health, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 101 medical devices industry deals worth $10.3bn were announced for the region in September 2022, against the 12-month average of 114 deals.
Of all the deal types, venture financing saw most activity in September 2022 with 76 transactions, representing a 75.3% share for the region.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In second place was M&A with 20 deals, followed by private equity deals with five transactions, respectively capturing a 19.8% and 5% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $9.07bn, while venture financing and private equity deals totalled $764.61m and $488m, respectively.
North America medical devices industry deals in September 2022: Top deals
The top five medical devices deals accounted for 91.5% of the overall value during September 2022.
The combined value of the top five medical devices deals stood at $9.44bn, against the overall value of $10.3bn recorded for the month.
The top five medical devices industry deals of September 2022 tracked by GlobalData were:
1) CVS Health’s $8bn acquisition deal with Signify Health
2) The $875m acquisition of Rx Savings Solutions by McKesson
3) Orbimed Advisors’s $250m private equity deal with Adaptive Biotechnologies
4) The $165m private equity of Theragun by HartBeat Ventures, North Castle Partners and Rx3 Ventures
5) Halma’s $154.02m acquisition deal with IZI Medical Products